ValuEngine upgraded shares of Zafgen (NASDAQ:ZFGN) from a strong sell rating to a sell rating in a research report sent to investors on Friday, February 2nd.
Separately, Zacks Investment Research upgraded Zafgen from a hold rating to a buy rating and set a $4.25 price target for the company in a research note on Saturday, November 11th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company’s stock. Zafgen currently has an average rating of Hold and a consensus target price of $6.63.
Zafgen (NASDAQ:ZFGN) opened at $7.92 on Friday. Zafgen has a one year low of $3.21 and a one year high of $8.95.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. 683 Capital Management LLC boosted its stake in Zafgen by 8.5% in the 3rd quarter. 683 Capital Management LLC now owns 1,300,000 shares of the biopharmaceutical company’s stock valued at $4,576,000 after purchasing an additional 101,600 shares during the period. Vanguard Group Inc. boosted its stake in Zafgen by 15.7% in the 2nd quarter. Vanguard Group Inc. now owns 883,838 shares of the biopharmaceutical company’s stock valued at $3,102,000 after purchasing an additional 119,902 shares during the period. Dimensional Fund Advisors LP boosted its stake in Zafgen by 31.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 584,159 shares of the biopharmaceutical company’s stock valued at $2,050,000 after purchasing an additional 140,848 shares during the period. Mangrove Partners bought a new stake in Zafgen in the 3rd quarter valued at $1,971,000. Finally, Royce & Associates LP boosted its stake in Zafgen by 65.0% in the 4th quarter. Royce & Associates LP now owns 548,491 shares of the biopharmaceutical company’s stock valued at $2,534,000 after purchasing an additional 216,000 shares during the period. Institutional investors and hedge funds own 48.63% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Zafgen (NASDAQ:ZFGN) Rating Increased to Sell at ValuEngine” was originally published by Week Herald and is the property of of Week Herald. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://weekherald.com/2018/02/12/zafgen-zfgn-raised-to-sell-at-valuengine.html.
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.